Evidence map›Paper›PMID 24978634›Full record

ReviewCurrent opinion in neurology2014

Treatment of advanced Parkinson's disease.

Juan C Giugni, Michael S Okun

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Quality of life outcomes after deep brain stimulation in acquired dystonia: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.Movement disorders : official journal of the Movement Disorder Society · 2017
    Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Juan C GiugniDepartments of Neurology and Neurosurgery, University of Florida Center for Movement Disorders and Neurorestoration, Gainesville, Florida, USA.
Michael S Okun

Funding

DBS Effects on Mood and Cognition in Parkinsons DiseaseK23NS044997 · NINDS · UNIVERSITY OF FLORIDA · PI OKUN, MICHAEL S · 2003 to 2007
$788k
Scheduled and Responsive Brain Stimulation for the Treatment of Tourette SyndromeR34MH080764 · NIMH · UNIVERSITY OF FLORIDA · PI OKUN, MICHAEL S · 2008 to 2010
$617k
Neural Correlates of Tourette SyndromeR21NS072897 · NINDS · UNIVERSITY OF MIAMI CORAL GABLES · PI OKUN, MICHAEL S, PRASAD, ABHISHEK · 2010 to 2011
$448k
NIMH NIH HHS R34 MH080764NINDS NIH HHS K23 NS044997NINDS NIH HHS R21 NS072897
6 · The paper itself

Abstract

purpose of reviewLater stage Parkinson's disease, sometimes referred to as advanced disease, has been characterized by motor complication, as well as by the potential emergence of nonlevodopa responsive motor and nonmotor symptoms. The management of advanced stage Parkinson's disease can be complex. This review summarizes the currently available treatment strategies for addressing advanced Parkinson's disease. RECENT

findingsWe will discuss the latest pharmacological strategies (e.g., inhibitors of dopamine-metabolizing enzymes, dopamine agonists, and extended release dopamine formulations) for addressing motor dysfunction. We will summarize the risks and benefits of current invasive treatments. Finally, we will address the current evidence supporting the treatment of nonmotor symptoms in the advanced Parkinson's disease patient. We will conclude by detailing the potential nonpharmacological and multidisciplinary approaches for advanced stage Parkinson's disease. SUMMARY: The optimization of levodopa is, in most cases, the most powerful therapeutic option available; however, medication optimization requires an advanced understanding of Parkinson's disease. Failure of conventional pharmacotherapy should precipitate a discussion of the potential risks and benefits of more invasive treatments. Currently, there are no comparative studies of invasive treatment. Among the invasive treatments, deep brain stimulation has the largest amount of existing evidence, but also has the highest individual per patient risk. Nonmotor symptoms will affect quality of life more than the motor Parkinson's disease symptoms, and these nonmotor symptoms should be aggressively treated. Many advanced Parkinson's disease patients will likely benefit from multi and interdisciplinary Parkinson's disease teams with multiple professionals collaborating to develop a collective and tailored strategy for an individual patient.

Indexed as

Antiparkinson AgentsHumansLevodopaParkinson DiseaseAntiparkinson AgentsLevodopa

Identifiers

PMID24978634
PMCPMC4140171

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.